MIR92B

Summary

MIR92B (microRNA 92b, HGNC:32920) is a microRNA gene on chromosome 1q22.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 693235 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32920
Approved symbol	MIR92B
Name	microRNA 92b
Location	1q22
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-92b
Ensembl gene	ENSG00000284586
Ensembl biotype	miRNA
Entrez	693235
RNAcentral	URS000075BA3A — ncRNA, 96 nt, 2 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000607575

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000607575 — 1 exons

Exon	Start	End
ENSE00003701541	155195177	155195272

Expression profiles

Bgee: expression breadth tissue_specific, 9 present calls, max score 89.07.

Top tissues by expression

9 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	89.07	gold quality
gastrocnemius	UBERON:0001388	77.97	gold quality
body of stomach	UBERON:0001161	63.56	gold quality
blood	UBERON:0000178	62.76	gold quality
omental fat pad	UBERON:0010414	58.57	gold quality
subcutaneous adipose tissue	UBERON:0002190	51.81	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	47.71	gold quality
skin of abdomen	UBERON:0001416	45.08	gold quality
left adrenal gland cortex	UBERON:0035825	40.60	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• hsa-miR-92b and hsa-miR-9/hsa-miR-9* represent excellent biomarkers for brain primary tumors (PMID:18624795)
• miR-92b suppresses bacterial peptide-induced proinflammatory responses in intestinal epithelial cells by inhibiting PepT1 expression. (PMID:21030610)
• miR-92b is overexpressed in glioma. (PMID:23416699)
• This study demonistrated that the miR-92b functions as a potential oncogene by targeting on Smad3 in glioblastomas. (PMID:23892108)
• this study further extends the biological role of miR-92b in non-small cell lung cancer A549 cells and for the first time identifies PTEN as a novel target of miR-92b. (PMID:24099768)
• MiR-92b may promote nonsmall cell lung cancer cell growth and motility partially by inhibiting RECK. (PMID:24162673)
• data indicates that miR-92b directly regulate cell proliferation and apoptosis by targeting DKK3 and act as prognostic factors for glioma patients (PMID:24325785)
• Data suggest that microRNA-92b up-regulates cell proliferation/cell migration/tumor invasiveness and down-regulates apoptosis of glioma cells via PTEN/Akt (phosphatase and tensin homolog protein/protein kinase b alpha) signaling pathway. (PMID:26893028)
• Low miR92b expression is associated with esophageal squamous cell carcinoma invasion and metastasis. (PMID:26934001)
• Reversion-inducing, cysteine-rich protein with kazal motifs (RECK) was identified as the direct and functional target of miR-92b in osteosarcoma (PMID:26993249)
• MiR-92b activates the beta-catenin signaling via nuclear translocation of beta-catenin in hepatocellular carcinoma cells. (PMID:27100897)
• our data provided evidence to verify that miR-92b was able to directly target DAB2IP, a well-known tumor suppressor, and inhibit epithelialmesenchymal transition of bladder cancer cells (PMID:27430302)
• Study shows significantly high plasma levels of miR-92b, 199a-5p, and 223 in uveal melanoma patients with monosomy-3, a predictor of metastasis. (PMID:27453764)
• Forced expression of MiR-92b decreased the mRNA and protein level of RAB23, and RAB23 rescued the biological functions of miR-92b. Taken together, this study revealed the oncogenic roles and the regulation of RAB23 in esophageal squamous cell carcinoma, suggesting RAB23 might be a therapeutic target (PMID:27659550)
• miR-92b/integrin alpha6/Akt axis controls the motility of esophageal squamous carcinoma cells. (PMID:28036265)
• Serum miR-92b-3p levels were significantly higher in Synovial Sarcoma patients in comparison to that in healthy individuals. Moreover, serum miR-92b-3p was robust in discriminating patients with Synovial Sarcoma from the other soft tissue sarcomas patients. (PMID:29116117)
• miR-92b-3p inhibition prevented colorectal cancer proliferation, invasion, and migration by upregulating FBXW7, which might suggest the potential role of miR-92b-3p in colorectal carcinogenesis and metastasis. (PMID:29638162)
• Serum Exosomal-miR-92b-5p expression was increased in Dilated Cardiomyopathy-Acute Heart Failure patients compared to the control group (Mann-Whitney U-test: P < 0.001). (PMID:29719295)
• miR-92b was up-regulated in cholangiocarcinoma compared with normal controls. The high level of miR-92b was associated with adverse outcomes in cholangiocarcinoma patients, which might be partly explained by the targeted genes of miR-92b and their signaling pathways. (PMID:29749758)
• Mechanistic studies in human breast cancer cell lines revealed that miR-92b directly targeted EZH2 promoting autophagy, and inhibiting the viability and invasion of breast cancer cells. (PMID:30066891)
• miR-92b-3p-TSC1 axis is critical for mTOR signaling-mediated vascular smooth muscle cell proliferation induced by hypoxia. (PMID:30518907)
• MIRN-92b inhibits p57kip2 expression in hepatocellular carcinoma tissues, thus enhancing the radio-resistance of hepatocellular carcinoma to ionizing radiation-based radiotherapy. (PMID:30544064)
• Downregulation of microRNA-92b-3p suppresses proliferation, migration, and invasion of gastric cancer SGC-7901 cells by targeting Homeobox D10. (PMID:31106881)
• MicroRNA-92b-5p modulates melatonin-mediated osteogenic differentiation of bone marrow mesenchymal stem cells by targeting ICAM-1. (PMID:31304676)
• circMTO1 directly interact with miR-92, and subsequently serves as a miRNA sponge to upregulate WWOX expression. (PMID:31456594)
• Circulating exosomal miR-92b was significantly down-regulated in colorectal cancer. (PMID:31588188)
• results suggest that miR-92b promotes gastric cancer (GC) cell proliferation by activating the DAB2IP-mediated PI3K/AKT signalling pathway. The miR-92b/DAB2IP/PI3K/AKT signalling axis may be a potential therapeutic target to prevent GC progression. (PMID:31713929)
• MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients. (PMID:31841197)
• Long Noncoding RNA NEAT1 Suppresses Proliferation and Promotes Apoptosis of Glioma Cells Via Downregulating MiR-92b. (PMID:31933377)
• miR-92b-3p was found to act as an oncomiR, promoting cell proliferation by downregulating TSC1 in clear cell renal cell carcinoma . (PMID:31975504)
• Lin28B/miR-92b Promote the Proliferation, Migration, and Invasion in the Pathogenesis of Preeclampsia via the DKK1/Wnt/beta-Catenin Pathway. (PMID:32072603)
• SEPT9_v2, frequently silenced by promoter hypermethylation, exerts anti-tumor functions through inactivation of Wnt/beta-catenin signaling pathway via miR92b-3p/FZD10 in nasopharyngeal carcinoma cells. (PMID:32138771)
• MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth. (PMID:32143670)
• MiR-92b inhibits proliferation and invasion of lung cancer by targeting EZH2. (PMID:32271434)
• MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients. (PMID:32538743)
• MicroRNA-92b acts as an oncogene by targeting PTEN/AKT in NSCLC. (PMID:32627866)
• Circulating miR-92b and miR-375 for monitoring the chemoresistance and prognosis of small cell lung cancer. (PMID:32728103)
• Recognition of nucleolin through interaction with RNA G-quadruplex. (PMID:32860827)
• MicroRNA-92b-3p promotes the progression of liver fibrosis by targeting CREB3L2 through the JAK/STAT signaling pathway. (PMID:33618248)
• Potential of peptide-engineered exosomes with overexpressed miR-92b-3p in anti-angiogenic therapy of ovarian cancer. (PMID:34047469)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.